These kinases include FGFR1, MAP2K3, MAPK1, MAPK3, and PIC3C3. A screen of possible kinase inhibitors found that GDC0994 (targeting the MAPK pathway) and PD173074 (targeting FGFR1) were able to reduce the IC50 of cisplatin in resistant osteosarcoma cell lines [373]. This evidence concerns the gene FGFR1 and osteosarcoma.